By interacting with RUNX1, a critical transcription factor, JMJD1C drives leukemia cell survival, making it a compelling therapeutic target. This discovery sheds light on how molecular mechanisms ...

RUNX1 and SF3B1 mutations significantly impact overall survival and progression to acute myeloid leukemia. Molecular profiling is crucial for better risk stratification in low-risk myelodysplastic ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with surgery. A team led by research hospital Massachusetts Eye and Ear and ...

They settled on an mRNA called RUNX1-Trap, which keeps RUNX1 in a cell's cytoplasm, preventing it from entering the nucleus and turning on the gene that turns the cells into scar tissue. They saw ...

Control of this program involves redirected chromatin occupancy of the PU.1 partner TF Runx1 to a lineage-inappropriate binding site repertoire. Hence, genomic reallocation of TF binding upon loss of ...

bState Key Laboratory of Cell Biology, Key Laboratory of Systems Biology, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, Shanghai Institute of ...

Despite the established link between RUNX1-FPD and hematologic malignancies, there remains a significant gap in understanding the cell-nonautonomous factors that contribute to clonal evolution and ...

The required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation. AML with KMT2A::MLLT3 and ...

Scientists have now identified the cause: although the additional chromosome 21 leads to increased gene dosage of many genes, it is above all the perturbation of the RUNX1 gene -- a gene that ...

It emerged that the RUNX1 gene is responsible for the chromosome's specific carcinogenic properties. In further analyses, the researchers were able to corroborate that only one particular variant ...

Hetty Carraway, MD: We also talked about patients with other types of mutations, such as IDH mutations or even RUNX1 or DNMT3A mutations. What’s your approach to this patient population? Eytan Stein, ...